Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.96 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | CCR2 | P41597 | 1/20 | 0.67 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28115310 | 1.00 | SIGMAR1 (0.96) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL10063607 | 1.00 | SIGMAR1 (0.96) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL8034018 | 0.98 | SIGMAR1 (0.92) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL9538814 | 0.98 | SIGMAR1 (0.92) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| Bromide SCHEMBL21961924 | 0.98 | SIGMAR1 (0.92) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL6138636 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL83548 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL152631 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL276363 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| Benzene SCHEMBL27761330 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CXCR4MEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351653-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2022261221-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-3256164-A2 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2017-12-20 | — | — | EP | claimed |
| WO-2016130539-A2 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-08-18 | — | — | WO | claimed |
| EP-0815091-A1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING AS (NO) | 1998-01-07 | — | — | EP | claimed |
| US-5705637-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1998-01-06 | — | — | US | claimed |
| US-5677446-A | Polyazacycloalkane compounds | NYCOMED IMAGING AS (NO) | 1997-10-14 | — | — | US | claimed |
| WO-1996028433-A1 | POLYAZACYCLOALKANE COMPOUNDS | NYCOMED IMAGING A.S (NO) | 1996-09-19 | — | — | WO | claimed |
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250295794-A1 | MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-09-25 | — | — | US | disclosed |
| US-12343401-B2 | Modular self assembly disassembly (SADA) technologies | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-07-01 | — | — | US | disclosed |
| US-11858993-B2 | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117247552-A | Mesoporous polyphosphazene microsphere and preparation method thereof | 陕西中医药大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023139203-A1 | COMPLEXES FOR CANCER TREATMENT AND IMAGING | Sciencons AS (NO) | 2023-07-27 | — | — | WO | disclosed |
| WO-1992004336-A1 | INTERMEDIATES FOR CHELATING AGENTS WITH PREFIXED SYMMETRY AND PROCESS FOR THEIR PREPARATION | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1992-03-19 | — | — | WO | disclosed |
| EP-0232751-B1 | 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECANE AND ANALOGS | E.R. Squibb & Sons, Inc. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
| EP-0255471-A1 | 1,4,7,10-Tetraazacyclododecane-derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | F13A1, CA13, MICA | SIGMAR1 3923/4885CXCR4 1812/4885MEN1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.